clinical trial · NCT06521255
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 244
DLBCLTafasitamabLenalidomideGemcitabineOxaliplatinRituximab
brief summary
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
started
May 7, 2024
primary completion
Sep 1, 2028
completion
Dec 1, 2029
last updated
Jul 25, 2024
official title
A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol